It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

Us­ing lab-grown pro­teins that are en­gi­neered to mim­ic the ar­chi­tec­ture of virus­es to in­duce an im­mune re­sponse, VBI Vac­cines is join­ing the hunt for a coro­n­avirus vac­cine — har­ness­ing tech­nol­o­gy that has ini­tial­ly been proved safe in ear­ly tri­als as a pro­phy­lac­tic for cy­tomegalovirus (CMV) in­fec­tion.

Un­like the raft of the com­pa­nies in the Covid-19 vac­cine race — in­clud­ing Mod­er­na, Cure­Vac and J&J — VBI is tak­ing a pan-coro­n­avirus ap­proach, by de­vel­op­ing a vac­cine that will en­com­pass Covid-19, se­vere acute res­pi­ra­to­ry syn­drome (SARS), and Mid­dle East res­pi­ra­to­ry syn­drome (MERS).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.